89 related articles for article (PubMed ID: 18708729)
1. Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen.
Kaechele V; von Wichert G; Adler G; Seufferlein T
Oncology; 2008; 74(3-4):123-6. PubMed ID: 18708729
[TBL] [Abstract][Full Text] [Related]
2. The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
Chong G; Cunningham D
Semin Oncol; 2005 Dec; 32(6 Suppl 9):S55-8. PubMed ID: 16399433
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
5. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Meyerhardt JA; Heseltine D; Ogino S; Clark JW; Enzinger PC; Ryan DP; Earle CC; Zhu AX; Fuchs CS
Clin Colorectal Cancer; 2006 May; 6(1):59-65. PubMed ID: 16796793
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].
Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328
[TBL] [Abstract][Full Text] [Related]
8. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS; Khambata-Ford S; Jonker DJ; O'Callaghan CJ; Tu D; Tebbutt NC; Simes RJ; Chalchal H; Shapiro JD; Robitaille S; Price TJ; Shepherd L; Au HJ; Langer C; Moore MJ; Zalcberg JR
N Engl J Med; 2008 Oct; 359(17):1757-65. PubMed ID: 18946061
[TBL] [Abstract][Full Text] [Related]
9. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
Khambata-Ford S; Garrett CR; Meropol NJ; Basik M; Harbison CT; Wu S; Wong TW; Huang X; Takimoto CH; Godwin AK; Tan BR; Krishnamurthi SS; Burris HA; Poplin EA; Hidalgo M; Baselga J; Clark EA; Mauro DJ
J Clin Oncol; 2007 Aug; 25(22):3230-7. PubMed ID: 17664471
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
[TBL] [Abstract][Full Text] [Related]
11. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.
Italiano A
Oncology; 2006; 70(3):161-7. PubMed ID: 16675911
[TBL] [Abstract][Full Text] [Related]
12. [Outcomes of cetuximab combination chemotherapy in clinical practice for patients with metastatic colorectal cancer].
Yamazaki T; Iwaya A; Katayanagi N
Gan To Kagaku Ryoho; 2013 Dec; 40(13):2529-33. PubMed ID: 24335364
[TBL] [Abstract][Full Text] [Related]
13. [Successes in late solid tumors. New therapy offer].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):71. PubMed ID: 15624667
[No Abstract] [Full Text] [Related]
14. [Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer].
Zhang XT; Shen L; Zhang XD; Li J; Zhang ZT
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):385-8. PubMed ID: 18953842
[TBL] [Abstract][Full Text] [Related]
15. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient.
Tonini G; Vincenzi B; Santini D; Olzi D; Lambiase A; Bonini S
J Natl Cancer Inst; 2005 Apr; 97(8):606-7. PubMed ID: 15840884
[No Abstract] [Full Text] [Related]
16. [Study into the use of cetuximab in metastatic colorectal cancer in a third level hospital].
Marín Pozo JF; Oya Alvarez de Morales B; Caba Porras I; Aranda García J
Farm Hosp; 2009; 33(2):72-9. PubMed ID: 19480794
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab in combination therapy: from bench to clinic.
Gerber DE; Choy H
Cancer Metastasis Rev; 2010 Mar; 29(1):171-80. PubMed ID: 20140759
[TBL] [Abstract][Full Text] [Related]
18. Clinical predictors of response to cetuximab-chemotherapy in metastatic colorectal cancer.
Ma AT; Ma BB; Lei KI; Mo FK; Chan AT
Hong Kong Med J; 2010 Jun; 16(3):207-12. PubMed ID: 20519757
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab targeted therapy: a new treatment paradigm for advanced colorectal cancer.
Chu E
Clin Colorectal Cancer; 2004 Feb; 3(4):205. PubMed ID: 15025791
[No Abstract] [Full Text] [Related]
20. Case series of cetuximab monotherapy for patients with pre-treated colorectal cancer complicated with hyperbilirubinemia due to severe liver metastasis.
Shitara K; Takahari D; Yokota T; Shibata T; Ura T; Muro K; Inaba Y; Yamaura H; Sato Y; Najima M; Utsunomiya S
Jpn J Clin Oncol; 2010 Mar; 40(3):275-7. PubMed ID: 19946122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
